Genenta Science SpA, a clinical-stage biotechnology company, is dedicated to the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company is headquartered in Milan, Italy.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-6.58M |
| Operating Margin | 0.00% |
| Return on Equity | -38.00% |
| Return on Assets | -17.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.06 |
| Price-to-Book | 3.06 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $48.22M |
| Float | $13.87M |
| % Insiders | 42.47% |
| % Institutions | 7.13% |
MILAN and NAPLES, Italy, July 23, 2026 (GLOBE NEWSWIRE) -- Sòphia High Tech S.r.l. (Sòphia HT), an Italian aerospace and defense company manufacturing critical parts for Europe's space and defense programs, backed by Genenta Science S.p.A.
Fiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of production increased 34.7% to €8.47 million EBITDA grew 68.1% to €1.61 million, expanding the EBITDA margin by approximately 380 basis points to 19.0% Operating profit advanced 80.8% to €1.21 million MILAN, July 22, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on aerospace, defense, biotech and Italian national-security-related technologies, today announced that the Board of Directors of Sòphia High Tech S.r.l.
Genenta signs Definitive Agreements with Sophia High Tech Genenta enters aerospace as it continues its strategic transformation into a next-generation ind
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GNTA and any ticker you trade — then tracks every position and per-strategy win rate.
